| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/08/2004 | US20040132829 Urogenital disorders |
| 07/08/2004 | US20040132828 Polymorphic forms of sertraline hydrochloride |
| 07/08/2004 | US20040132827 Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions |
| 07/08/2004 | US20040132826 Modified release compositions of milnacipran |
| 07/08/2004 | US20040132825 Methods of treating cancer with HDAC inhibitors |
| 07/08/2004 | US20040132824 Novel methods and compositions for alleviating pain |
| 07/08/2004 | US20040132823 Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
| 07/08/2004 | US20040132822 Crystalline solid form of (2S,5Z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid |
| 07/08/2004 | US20040132821 acetyl-L-carnitine and a mixture of polyphenols containing hydroxytyrosol; preventing tissue damage caused by free radicals, diabetic or toxic neuropathies and metabolic disorders of glucose utilization |
| 07/08/2004 | US20040132820 exogenous leukotriene B4 (LTB4), variants and derivatives; prophylaxis and treatment of cancers induced by tumor viruses and in other neoplasic diseases |
| 07/08/2004 | US20040132819 Appetite control method |
| 07/08/2004 | US20040132818 dicarboxylic acids and derivatives; hypolipidemic effect based on activating plasma lipoproteins clearance resulting from decrease in plasma apo C-III; insulin sensitizers; treating obesity by increase in calorigenesis |
| 07/08/2004 | US20040132817 Particularly useful inhibitors are sodium butyrate, phenyl butyrate and trichostatin A. |
| 07/08/2004 | US20040132816 Lipid metabolism and fructus crataegus |
| 07/08/2004 | US20040132815 sulfodehydroabietic acid or a salt thereof; may be administered as a gargle, a liniment, a patch, a spray, a troche or a buccal preparation. |
| 07/08/2004 | US20040132814 Pharmaceutical compositions |
| 07/08/2004 | US20040132813 Glycerol-lactate esters for use as an energy supplement during exercise and recovery |
| 07/08/2004 | US20040132811 Methods and products for inhibiting growth of fungal pathogens on turfgrass |
| 07/08/2004 | US20040132810 Odorless formulation for treating mucosal discontinuities |
| 07/08/2004 | US20040132809 Cell adhesion inhibitors |
| 07/08/2004 | US20040132808 precipitating the citalopram base in crystalline form, and transforming the base into a pharmaceutically acceptable citalopram salt; useful for removing intermediates which are structurally closely related to citalopram |
| 07/08/2004 | US20040132807 Aurones as telomerase inhibitors |
| 07/08/2004 | US20040132806 polymeric coating with a pH-independent dissolution profile that inhibits the release of the pravastatin in the stomach, and permits release in the intestine; side effect reduction |
| 07/08/2004 | US20040132805 preferably also contains a compound that donates, transfers, releases or induces production of nitric oxide and a hydralazine antioxidant; for treating and/or preventing a vascular disease characterized by nitric oxide insufficiency |
| 07/08/2004 | US20040132804 1-aminoindane derivatives, e.g., 1-(cyclopentylcarbonylamino)-5-(4-cyclopropyl-2-(phenylsulfonyl)phenylsulfonyl)indane; exhibit anti-inflammatory and immunomodulatory activity |
| 07/08/2004 | US20040132803 compound having a slowly-inactivating A-type K+ channel opening activity, particularly N-(5,5-dioxido-10-oxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide |
| 07/08/2004 | US20040132802 delaying release of a poorly water soluble statin, especially simvastatin and/or lovastatin, for a time sufficient to avoid exposure of said statin to the stomach, duodenum, and jejunum; and releasing said statin in the ileum, colon, or both |
| 07/08/2004 | US20040132801 Therapeutic proline derivatives |
| 07/08/2004 | US20040132800 aminomethyl- or ethyl-substituted indoles, tetrahydrocarbazoles and tetrahydropyrido[1,2-a]indoles |
| 07/08/2004 | US20040132799 Aminoalkoxyindoles and methods of use |
| 07/08/2004 | US20040132798 containing a benzonitrile group and N-substituted with a tert-butylcarbonylmethyl- or a tert-butyloxycarbonylaminoethyl- group; particularly in a gelling polymer matrix to form modified release composition |
| 07/08/2004 | US20040132797 treating of or preventing relapse of depression, anxiety disorders, eating disorders, or urinary incontinence |
| 07/08/2004 | US20040132796 Novel intermediates for use in retinoid synthesis |
| 07/08/2004 | US20040132795 identifying mutations in the TIGR gene of a glaucomatous patient and treating them with a non-steroidal anti-inflammatory drug |
| 07/08/2004 | US20040132794 Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them |
| 07/08/2004 | US20040132792 Oxazoles as mGluR 1 enhancers |
| 07/08/2004 | US20040132791 N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication |
| 07/08/2004 | US20040132789 Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin |
| 07/08/2004 | US20040132788 thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives; treating neurodegenerative disorders or pain. |
| 07/08/2004 | US20040132786 Differential tumor cytotoxicity compounds and compositions |
| 07/08/2004 | US20040132784 1-optionally protected hydroxy-2-aminoalkylaryl compounds, especially in which the amino and hydroxy groups are joined by a carbonyl to form an oxazolidinone ring; immunosuppressants |
| 07/08/2004 | US20040132782 Aspartyl protease inhibitors |
| 07/08/2004 | US20040132781 Pyrazole compounds useful as protein kinase inhibitors |
| 07/08/2004 | US20040132780 Method and compositions for treating migraines |
| 07/08/2004 | US20040132778 Method for treating retroviral infections |
| 07/08/2004 | US20040132776 Use of benzothiopenes to treat and prevent prostate cancer |
| 07/08/2004 | US20040132773 Method of treating neurodgenerative disorders of the retina and optic nerve head |
| 07/08/2004 | US20040132772 1-carbonyl-4-carbonylaminotetrahydroquinoline derivatives; especially treating asthma and allergic rhinitis |
| 07/08/2004 | US20040132771 solid amorphous adsorbate provides concentration enhancement of the CETP inhibitor resulting in improved bioavailability |
| 07/08/2004 | US20040132770 Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen |
| 07/08/2004 | US20040132769 Certain phenylacetic acids and derivatives |
| 07/08/2004 | US20040132768 substituted with (hetero)aryl carbonyloxy group and quaternized, e.g., 3(R)-Diphenylacetoxy-1-(3-phenoxy-propyl)-1-azoniabicyclo[2.2.2]octane; bromide; antimuscarinic agents for treating COPD, chronic bronchitis, asthma and rhinitis. |
| 07/08/2004 | US20040132764 Antibiotics for the treatment of infections in acidic environments |
| 07/08/2004 | US20040132763 of carboxylic acids, such as maleic or glycolic acid; treating breast cancer, colon cancer, lung cancer, renal cancer and prostate cancer. |
| 07/08/2004 | US20040132762 Sulfonamide and sulfamide substituted imidazoquinolines |
| 07/08/2004 | US20040132761 water or a water/ethanol mixture as solvent; acid for achieving a pH of 2.0-4.5; and a preservative; optionally including a complexing agent, stabilizer, a pharmacologically acceptable cosolvent, and other adjuvants and additives |
| 07/08/2004 | US20040132759 acid addition salt of optionally substituted 5-[2-(indan-2-ylamino-1-hydroxyethyl)]-8-hydroxyquinolone; treating respiratory disorders, especially asthma and COPD |
| 07/08/2004 | US20040132758 hyterocyclylaminomethyl- or aminocarbonyl-substituted 9,10-ethanoanthracenes or their aza derivatives; treating obesity, diabetes, inflammatory and immune disorders |
| 07/08/2004 | US20040132757 Triazospiro compounds having nociceptin receptor affinity |
| 07/08/2004 | US20040132756 incorporating tartaric acid in a solid preparation having a high content of a quinolone compound, particularly sitafloxacin; reduced in fluctuations of oral absorption |
| 07/08/2004 | US20040132754 signal transduction inhibitor is a PDGF receptor tyrosine kinase inhibitor or an active ingredient which decreases the activity of the epidermal growth factor; antiproliferative agent |
| 07/08/2004 | US20040132751 Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops |
| 07/08/2004 | US20040132750 Acyl guanidine compounds and use thereof |
| 07/08/2004 | US20040132747 Novel heteroaryl derivatives and their use as medicaments |
| 07/08/2004 | US20040132746 2-substituted 4-pyrrolyl-pyrimidines, e.g., 2-[N-(phenyl)]-4-(2,4-dimethylpyrrol-3-yl)pyrimidineamines in which the phenyl group is 2-, 3-, 4-or 5-substituted by at least one of F, NH2, NO2, OH, Cl, Br, I, CN, CH2OH, CF3 or OMe. |
| 07/08/2004 | US20040132744 lower gastrointestinal and cardiovascular side effects; use in treatment of respiratory system disorders, as tokolitics and as antiallergics, for eye applications. |
| 07/08/2004 | US20040132743 Amorphous form of (-)-[2-[4-[(4-Chlorophenyl)-phenyl methyl]-1- piperazinyl] ethoxy] acetic acid dihydrochloride (levocetirizine dihydrochloride) |
| 07/08/2004 | US20040132741 N-sulfonylindoles and N-sulfonylindazoles; treating motor disorders, anxiety disorders or cognitive disorders, such as schizophrenia, depression, Alzheimer's disease or Parkinson's disease |
| 07/08/2004 | US20040132740 structurally related to compounds such as ciprofloxacin but without the carboxylic acid or ester functionality, are not only also highly effective as antibiotics, but show a superior antibacterial effect. |
| 07/08/2004 | US20040132739 e.g. RO 28-2653 in combination with Cisplatin, Paclitaxel, Gemcitabine or Etoposide; treating patients with solid metastasized or non-metastasized tumors |
| 07/08/2004 | US20040132737 especially dimethylphenylpiperazinium; treating a variety of pulmonary diseases with fewer side effects than other anti-inflammatory drugs, such as steroids |
| 07/08/2004 | US20040132736 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 07/08/2004 | US20040132735 Beta-carboline derivatives and its pharmaceutical use aginst depression and anxiety |
| 07/08/2004 | US20040132734 Azaindoles having serotonin receptor affinity |
| 07/08/2004 | US20040132729 Inhibitors of p38 |
| 07/08/2004 | US20040132727 Quinoline and quinazoline derivatives and drugs containing the same |
| 07/08/2004 | US20040132725 tyrphostin preparations enriched in certain geometric isomers; treating protein tyrosine kinase related disorders. especially with slow release formulations |
| 07/08/2004 | US20040132724 e.g., cis-1-Acetyl-6-ethyl-N-(4-ethylphenyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinamine; atopic dermatitis, urticaria, various allergies bullous pemphigoid, industrial sensitization, chronic transplant rejection and COPD |
| 07/08/2004 | US20040132722 Glycoprotein-mediated MDR |
| 07/08/2004 | US20040132721 Treatment of airway disorders |
| 07/08/2004 | US20040132720 Antidepressants |
| 07/08/2004 | US20040132718 Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| 07/08/2004 | US20040132717 2-Oxo-piperidinyl-and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders |
| 07/08/2004 | US20040132716 CGRP antagonists |
| 07/08/2004 | US20040132715 Method to treat allergic rhinitis |
| 07/08/2004 | US20040132712 Together with one or more pharmaceutically active ingredients, e.g. antibiotics, to prevent or reduce rapid degradation of the active ingredient by bacteria |
| 07/08/2004 | US20040132710 Lactams as tachkinin antagonists |
| 07/08/2004 | US20040132706 Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension |
| 07/08/2004 | US20040132705 Inhibitors of thromboxane formation and action |
| 07/08/2004 | US20040132704 Use of oculosurface selective glucocorticoid in the treatment of dry eye |
| 07/08/2004 | US20040132703 Methods for treating migraine |
| 07/08/2004 | US20040132702 luminally active anti-inflammatory or immunosuppressive compound with minimal or no systemic side effects |
| 07/08/2004 | US20040132701 Steroid hormones, especially the oestrogens |
| 07/08/2004 | US20040132700 Use of fluticasone propionate in the treatment of diseases ameliorated by enhancement of epithelial madrix adhesion such as asthma cystic fibrosis and influenza |
| 07/08/2004 | US20040132699 Skin disorders |
| 07/08/2004 | US20040132698 Androgen as a male contraceptive and non-contraceptive androgen replacement |
| 07/08/2004 | US20040132697 Administering an adrenergic receptor antagonist; 5-cyclopropyl-7-methoxy-2-(2-([dimethylamino]methyl)-7,8-dihydro[1,6]naphthyridin-6(5H)-yl)-4(3H)-quinazolinone; drug screening |
| 07/08/2004 | US20040132696 Therapeutic agents for pigmentation and melanocyte growth inhibitory agents |
| 07/08/2004 | US20040132694 6-Chloro-3-(3,4-dioxo-2-phenylamino-cyclobut-1-enylamino)-2-hydroxy-benzamide; psoriasis, atopic dermatitis, arthritis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease |
| 07/08/2004 | US20040132692 A freeze drying mixture comprising an epothilone and a cyclodextrin; antiproliferative agent, anticarcinogenic agent; cancer, psoriasis, restenosis, multiple sclerosis, rheumatoid arthritis, atherosclerosis; side effect reduction |